글로벌 엑산테마 시장 – 2029년까지의 산업 동향 및 예측

엑산테마 시장 분석 및 규모

글로벌 발진 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 특히 유아에서 바이러스성 발진의 발생률 증가, 백신 접종에 대한 정부 이니셔티브 증가, 바이러스성 발진에 대한 약물 개발을 위한 연구 활동 증가는 발진 시장을 활성화할 것입니다. 지속적인 약물 발견과 정부 및 비정부 조직 이니셔티브를 포함하는 의학적 발전은 시장 성장을 촉진하는 것입니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

Data Bridge Market Research는 2022-2029년 예측 기간 동안 글로벌 발진증 시장의 성장률을 분석합니다. 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

시장 정의

발진은 바이러스 감염에 의해 유발되는 피부 발진 질환의 일종입니다. 인간 헤르페스 바이러스 6(HH6)으로 알려진 바이러스에 의해 발생하며, 독소를 생성하여 유기체 화학 물질 또는 면역 반응에 의해 피부를 손상시킵니다. 2세 이하의 어린이에게 가장 흔히 영향을 미칩니다. 증상으로는 두통, 심한 복통, 설사, 구토 등이 있습니다. 발진은 머리부터 발끝까지 나타나며 붉고 얼룩덜룩합니다. 의료 분야에 매우 중요하므로 예측 기간 동안 크게 증가할 것으로 예상됩니다.

발진 시장 범위 및 세분화

Global Exanthema Market Dynamics

Drivers

• More Exposure of Microorganisms Due to Bacteria

Exanthema can occur due to the exposure to many microorganisms, toxins, or drugs. It eventually can spread out and the rashes turn out to be itchy. Children are more exposed to such rashes and at times it gets tough to differentiate just by core appearance. Thus, it boosts the market growth

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased Awareness and Medical Facilities

The rising awareness about exanthema and their possible treatment facilities are most likely to help in the expansion of the global exanthema market. In addition, improving medical facilities and increasing number of R&D activities for better remedies to the diseases are most likely to help create new growth opportunities for this market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global exanthema market over a forecast period.

• Increasing Cost of Treatment Therapeutics

Even though the disease prevalence is increasing, but along with it, the drug costs are also increasing. These rising treatment costs are restraining the market growth.   

This global emphysema market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global emphysema market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Exanthema Market Scope

The global exanthema market is segmented on the basis of types, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Bacterial
• Viral
• Others

Treatment

• Anti-Pyretic
• Emollients
•  Liquids
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Exanthema Market Regional Analysis/Insights

The global exanthema market is analysed and market size insights and trends are provided by types, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global exanthema market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to large number of patients diagnosed with exanthema viral infection and increased government initiatives for vaccination.

Asia-Pacific dominates the market due to rise prevalence of exanthema viral infection & continuous rise in population and rapidly improving health care infrastructure in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Exanthema Market Share Analysis

The global exanthema market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global exanthema market.

Key players operating in the global exanthema market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG(독일)
• 히크마제약(일본)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 브리스톨 마이어스 스퀴브 회사(미국)
• GSK 주식회사(영국)
• Bayer AG(독일)
• Sun Pharmaceutical Industries Ltd(인도)
• 노바티스 AG(스위스)
• Dr. Reddy's Laboratories Ltd(인도)
• Perrigo Company plc (아일랜드)

SKU-53950